In:
Pharmacogenomics, Future Medicine Ltd, Vol. 17, No. 15 ( 2016-10), p. 1687-1691
Abstract:
Aim: Our aim was to explore the influence of 9-bp insertion/deletion and variable number of 9 bp elements (63/91) length polymorphism in noncoding interfering RNA and major promoter of DHFR gene on methotrexate (MTX) efficacy and toxicity in patients with rheumatoid arthritis (RA). Patients & methods: Response to the MTX therapy and adverse effects were estimated in 243 RA patients genotyped for the selected polymorphism. Results: The presence of allele 1 of analyzed polymorphism had significant protective effect against MTX toxicity (odds ratio: 0.37 [95% CI: 0.19–0.70]; p = 0.002). Results remained significant in multiple logistic regression analysis with the inclusion of disease and treatment features in the model (p = 0.03). Conclusion: Polymorphism 63/91 in DHFR gene promoter can modulate the onset of MTX-related adverse effects in RA patients.
Type of Medium:
Online Resource
ISSN:
1462-2416
,
1744-8042
DOI:
10.2217/pgs-2016-0090
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2016
SSG:
15,3